Literature DB >> 12122212

The crystal structure of human CD21: Implications for Epstein-Barr virus and C3d binding.

Andrea E Prota1, David R Sage, Thilo Stehle, Joyce D Fingeroth.   

Abstract

Human complement receptor type 2 (CD21) is the cellular receptor for Epstein-Barr virus (EBV), a human tumor virus. The N-terminal two short consensus repeats (SCR1-SCR2) of the receptor interact with the EBV glycoprotein gp350/220 and also with the natural CD21 ligand C3d. Here we present the crystal structure of the CD21 SCR1-SCR2 fragment in the absence of ligand and demonstrate that it is able to bind EBV. Based on a functional analysis of wild-type and mutant CD21 and molecular modeling, we identify a likely region for EBV attachment and demonstrate that this region is not involved in the interaction with C3d. A comparison with the previously determined structure of CD21 SCR1-SCR2 in complex with C3d shows that, in both cases, CD21 assumes compact V-shaped conformations. However, our analysis reveals a surprising degree of flexibility at the SCR1-SCR2 interface, suggesting interactions between the two domains are not specific. We present evidence that the V-shaped conformation is induced by deglycosylation of the protein, and that physiologic glycosylation of CD21 would result in a more extended conformation, perhaps with additional epitopes for C3d binding.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12122212      PMCID: PMC124999          DOI: 10.1073/pnas.162360499

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Solution structure and dynamics of the central CCP module pair of a poxvirus complement control protein.

Authors:  C E Henderson; K Bromek; N P Mullin; B O Smith; D Uhrín; P N Barlow
Journal:  J Mol Biol       Date:  2001-03-16       Impact factor: 5.469

2.  Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21).

Authors:  L Clemenza; D E Isenman
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

3.  Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding.

Authors:  W L Martin; A P West; L Gan; P J Bjorkman
Journal:  Mol Cell       Date:  2001-04       Impact factor: 17.970

4.  Site-specific mutagenesis using synthetic oligodeoxyribonucleotide primers: I. Optimum conditions and minimum ologodeoxyribonucleotide length.

Authors:  S Gillam; M Smith
Journal:  Gene       Date:  1979-12       Impact factor: 3.688

5.  Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons.

Authors:  A Nicholls; K A Sharp; B Honig
Journal:  Proteins       Date:  1991

6.  Identification of murine complement receptor type 2.

Authors:  J D Fingeroth; M A Benedict; D N Levy; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

7.  Biochemical and antigenic analysis of the Epstein Barr virus/C3d receptor (CR2).

Authors:  M F Siaw; G R Nemerow; N R Cooper
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

8.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.

Authors:  J D Fingeroth; J J Weis; T F Tedder; J L Strominger; P A Biro; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

9.  Characterization of a T-lymphocyte Epstein-Barr virus/C3d receptor (CD21).

Authors:  J D Fingeroth; M L Clabby; J D Strominger
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

10.  Crystal structure of two CD46 domains reveals an extended measles virus-binding surface.

Authors:  J M Casasnovas; M Larvie; T Stehle
Journal:  EMBO J       Date:  1999-06-01       Impact factor: 11.598

View more
  19 in total

1.  CR2+ marginal zone B cell production of pathogenic natural antibodies is C3 independent.

Authors:  Keith M Woods; Michael R Pope; Sara M Hoffman; Sherry D Fleming
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

2.  Immunophysical properties and prediction of activities for vaccinia virus complement control protein and smallpox inhibitor of complement enzymes using molecular dynamics and electrostatics.

Authors:  Li Zhang; Dimitrios Morikis
Journal:  Biophys J       Date:  2006-02-10       Impact factor: 4.033

3.  The structure of C2b, a fragment of complement component C2 produced during C3 convertase formation.

Authors:  Vengadesan Krishnan; Yuanyuan Xu; Kevin Macon; John E Volanakis; Sthanam V L Narayana
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-02-20

4.  Mapping of the C3d ligand binding site on complement receptor 2 (CR2/CD21) using nuclear magnetic resonance and chemical shift analysis.

Authors:  James M Kovacs; Jonathan P Hannan; Elan Z Eisenmesser; V Michael Holers
Journal:  J Biol Chem       Date:  2009-01-21       Impact factor: 5.157

Review 5.  Molecular structure and expression of anthropic, ovine, and murine forms of complement receptor type 2.

Authors:  Dong Liu; Jian-Ying Zhu; Zhong-Xiang Niu
Journal:  Clin Vaccine Immunol       Date:  2008-04-09

6.  Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.

Authors:  Kendra A Young; Andrew P Herbert; Paul N Barlow; V Michael Holers; Jonathan P Hannan
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

7.  Constrained solution scattering modelling of human antibodies and complement proteins reveals novel biological insights.

Authors:  Stephen J Perkins; Azubuike I Okemefuna; Ruodan Nan; Keying Li; Alexandra Bonner
Journal:  J R Soc Interface       Date:  2009-07-15       Impact factor: 4.118

8.  Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.

Authors:  Javier G Ogembo; Lakshmi Kannan; Ionita Ghiran; Anne Nicholson-Weller; Robert W Finberg; George C Tsokos; Joyce D Fingeroth
Journal:  Cell Rep       Date:  2013-02-14       Impact factor: 9.423

9.  Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection.

Authors:  Mohamed S Arredouani; Manoj K Bhasin; David R Sage; Laura K Dunn; Michael B Gill; Deep Agnani; Towia A Libermann; Joyce D Fingeroth
Journal:  J Virol       Date:  2014-03-05       Impact factor: 5.103

10.  Biophysical investigations of complement receptor 2 (CD21 and CR2)-ligand interactions reveal amino acid contacts unique to each receptor-ligand pair.

Authors:  James M Kovacs; Jonathan P Hannan; Elan Z Eisenmesser; V Michael Holers
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.